ATE541582T1 - Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen - Google Patents

Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen

Info

Publication number: ATE541582T1
Authority: AT; Austria
Prior art keywords: glp; peptide compositions; stabilized pharmaceutical; peptide; pharmaceutical
Prior art date: 2003-06-03

Application number

AT04735870T

Other languages

English (en)

Inventor

Claus Juul-Mortensen

Dorte Engelund

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-03

Filing date

2004-06-03

Publication date

2012-02-15

2004-06-03 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2004-06-03 Priority claimed from PCT/DK2004/000380 external-priority patent/WO2004105781A2/en

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE541582T1 publication Critical patent/ATE541582T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
239000000203 mixture Substances 0.000 title 1
108010088406 Glucagon-Like Peptides Proteins 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000007935 neutral effect Effects 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Dermatology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dispersion Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

AT04735870T 2003-06-03 2004-06-03 Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen ATE541582T1 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DKPA200300819		2003-06-03
US47627903P	2003-06-05	2003-06-05
DKPA200400075		2004-01-19
US53852504P	2004-01-22	2004-01-22
PCT/DK2004/000380 WO2004105781A2 (en)	2003-06-03	2004-06-03	Stabilized pharmaceutical peptide compositions

Publications (1)

Publication Number	Publication Date
ATE541582T1 true ATE541582T1 (de)	2012-02-15

Family

ID=36645905

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04735870T ATE541582T1 (de)	2003-06-03	2004-06-03	Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen

Country Status (8)

Country	Link
US (2)	US7632806B2 (de)
EP (1)	EP2292254A3 (de)
JP (1)	JP4936884B2 (de)
KR (1)	KR101308912B1 (de)
CN (1)	CN102940879B (de)
AT (1)	ATE541582T1 (de)
BR (1)	BRPI0410972C1 (de)
ES (1)	ES2380437T3 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003072143A1 (en) *	2002-02-27	2003-09-04	Pharmain, Ltd.	Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en)	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1633391B1 (de) *	2003-06-03	2011-10-19	Novo Nordisk A/S	Stabilisierte pharmazeutische peptid zusammensetzungen
WO2005112977A2 (en) *	2004-04-23	2005-12-01	Pharmain, Ltd.	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
KR101529318B1 (ko)	2005-12-19	2015-06-16	파마인 코포레이션	치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
MX2008014870A (es)	2006-05-30	2009-02-12	Intarcia Therapeutics Inc	Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (de)	2006-08-09	2012-11-14	Intarcia Therapeutics, Inc.	Osmotische freisetzungssysteme und kolbenanordnungen
HRP20130259T1 (hr)	2007-04-23	2013-04-30	Intarcia Therapeutics, Inc.	Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
KR100746658B1 (ko)	2007-04-23	2007-08-06	성균관대학교산학협력단	소수성 담즙산이 접합된 엑센딘-4 유도체, 이의 제조방법및 이를 포함하는 약학 조성물
US7960336B2 (en) *	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) *	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
DK2240155T3 (da)	2008-02-13	2012-09-17	Intarcia Therapeutics Inc	Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
JP2011516541A (ja) *	2008-04-07	2011-05-26	ナショナルインスティテュートオブイミュノロジー	糖尿病および他の慢性疾患の治療に有用な組成物
SMT201700583T1 (it)	2009-09-28	2018-01-11	Intarcia Therapeutics Inc	Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
BR112012012945A2 (pt)	2009-11-25	2020-12-29	Arisgen Sa	Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
WO2011143788A1 (en) *	2010-05-17	2011-11-24	Zhejiang Beta Pharma Inc.	Novel glucagon like peptide analogs, composition, and method of use
US8636711B2 (en) *	2010-06-14	2014-01-28	Legacy Emanuel Hospital & Health Center	Stabilized glucagon solutions and uses therefor
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2526971A1 (de)	2011-05-25	2012-11-28	ArisGen SA	Mukosale Freisetzung von Arzneimitteln
EP2895506A1 (de)	2012-09-17	2015-07-22	Imperial Innovations Limited	Peptidanaloga von glucagon und glp1
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en)	2012-12-21	2016-05-20	Sanofi	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
SMT201700401T1 (it) *	2013-06-28	2017-09-07	Amgen Inc	Formulazione liquida stabile di amg 416 (velcalcetide)
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (de)	2013-12-13	2016-10-19	Sanofi	Nicht-acylierte exendin-4-peptidanaloga
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
EP3160491A4 (de) *	2014-06-25	2018-01-17	GlaxoSmithKline LLC	Pharmazeutische zusammensetzungen
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en)	2015-06-03	2021-02-23	Intarcia Therapeutics, Inc.	Implant placement and removal systems
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
RU2760007C2 (ru)	2016-05-16	2021-11-22	Интарсия Терапьютикс, Инк.	Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
CN110225762A (zh)	2017-01-03	2019-09-10	因塔西亚制药公司	包括glp-1受体激动剂的连续施用和药物的共同施用的方法
KR102568413B1 (ko)	2017-06-15	2023-08-21	한국전자통신연구원	이온 빔 치료장치
HRP20240485T1 (hr) *	2017-08-24	2024-07-05	Novo Nordisk A/S	Pripravci glp-1 i njihova upotreba
CN110551203B (zh) *	2019-09-25	2023-02-10	成都奥达生物科技有限公司	一种艾塞那肽类似物
PE20230819A1 (es)	2020-02-18	2023-05-19	Novo Nordisk As	Composiciones y usos de glp-1
EP4142695B1 (de) *	2020-04-29	2025-11-05	Novo Nordisk A/S	Feste zusammensetzungen mit einem glp-1-agonisten und histidin
EP4281039A2 (de)	2021-01-25	2023-11-29	Mylan Ireland Limited	Pharmazeutische glp-peptid-zusammensetzungen und verfahren zu ihrer herstellung
CN118307645A (zh) *	2021-05-28	2024-07-09	广东众生睿创生物科技有限公司	多肽的制备及其应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4468346A (en) *	1983-10-27	1984-08-28	The United States Of America As Represented By The Secretary Of Agriculture	Monoclonal antibodies to porcine immunoglobulins
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
WO1988008673A1 (en) *	1987-05-14	1988-11-17	Commonwealth Scientific And Industrial Research Or	Whey protein fractions
EP0422124A4 (en)	1988-06-27	1991-10-16	Genex Corporation	Thermal release of recombinant protein into culture media
EP0431679B1 (de)	1989-12-05	1994-10-19	Merck & Co. Inc.	Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe
DE4002066A1 (de)	1990-01-25	1991-08-01	Basf Ag	Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
US5272135A (en) *	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (sv)	1991-05-07	1991-05-07	Tomas Moks	Peptide hormone solution
US5206219A (en) *	1991-11-25	1993-04-27	Applied Analytical Industries, Inc.	Oral compositions of proteinaceous medicaments
DE69307505T2 (de)	1992-05-13	1997-07-24	Sandoz-Patent-Gmbh, 79539 Loerrach	Opthalmische zusammensetzungen enthaltend ein cyclosporin
US6284727B1 (en) *	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
GB9320782D0 (en)	1993-10-08	1993-12-01	Univ Leeds Innovations Ltd	Stabilising of proteins on solution
DE69422637T2 (de)	1993-11-19	2000-06-08	G.D. Searle & Co., Chicago	Transdermale zusammensetzung von n-(n-(5-(4-(aminoiminomethyl)phenyl-1-oxopentyl)-l-alpha-aspartyl)-l-phenylalanin oder deren esterderivaten und ihre pharmazeutischverwendbaren salze
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
AU1847695A (en)	1994-02-22	1995-09-04	Syntex-Synergen Neuroscience Joint Venture, The	Pharmaceutical formulations of cntf
US5652216A (en) *	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
CA2157219C (en)	1994-08-31	2010-10-05	Munehiro Noda	Process for purifying recombinant human serum albumin
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
EP0796106B1 (de)	1994-12-23	2003-03-19	Novo Nordisk A/S	Glp-1 zusammensetzungen mit verlängerter wirkdauer
US6184201B1 (en) *	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) *	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
CN1114613C (zh)	1995-06-02	2003-07-16	诺沃奇梅兹有限公司	蛋白质溶液的铝/铁处理和膜浓缩方法
US5631347A (en)	1995-06-07	1997-05-20	Eli Lilly And Company	Reducing gelation of a fatty acid-acylated protein
IL128332A0 (en)	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
US6384016B1 (en) *	1998-03-13	2002-05-07	Novo Nordisk A/S	Stabilized aqueous peptide solutions
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
KR20000070338A (ko) *	1997-01-20	2000-11-25	나가시마 카쭈시게, 노미야마 아키히코	펩티드의 안정화 방법 및 당해 방법을 이용한 펩티드 함유 동결건조 의약조성물
CA2236519C (en) *	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
AU4894697A (en)	1997-10-01	1999-04-23	Flemington Pharmaceutical Corporation	Buccal, polar and non-polar spray or capsule
IL135087A (en)	1997-10-24	2005-05-17	Genentech Inc	Process for purifying peptides, polypeptides and biologically active non-peptidyl compounds
JP2001525371A (ja) *	1997-12-05	2001-12-11	イーライ・リリー・アンド・カンパニー	Ｇｌｐ−１製剤
US6380357B2 (en) *	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
AU2712899A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
JP2003522099A (ja) *	1998-02-27	2003-07-22	ノボノルディスクアクティーゼルスカブ	遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
JP2002512175A (ja)	1998-02-27	2002-04-23	ノボノルディスクアクティーゼルスカブ	Ｇｌｐ−１類似体の誘導体類
EP1061946B1 (de)	1998-02-27	2004-04-28	Novo Nordisk A/S	Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
EP1062240B1 (de)	1998-02-27	2010-04-28	Novo Nordisk A/S	N-terminal veränderte glp-1 abkömmlinge
CN1317967A (zh) *	1998-09-17	2001-10-17	伊莱利利公司	蛋白质制剂
DE69922043T2 (de)	1998-12-07	2005-11-24	Société de Conseils de Recherches et d'Applications Scientifiques S.A.S.	Glp-1 analoge
AU2373400A (en) *	1998-12-22	2000-07-12	Eli Lilly And Company	Shelf-stable formulation of glucagon-like peptide-1
NZ512663A (en)	1999-01-14	2004-05-28	Amylin Pharmaceuticals Inc	Novel exendin agonist formulations and methods of administration thereof
US6444788B1 (en) *	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
EP1956000B1 (de)	1999-03-17	2016-10-05	Novo Nordisk A/S	Acylierungsmittel zur acylierung von peptiden
WO2001000223A2 (en)	1999-06-25	2001-01-04	Minimed Inc.	Multiple agent diabetes therapy
US6569832B1 (en) *	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
PT1242121E (pt)	1999-12-16	2005-05-31	Lilly Co Eli	Composicoes polipeptidicas com estabilidade melhorada
US7022674B2 (en)	1999-12-16	2006-04-04	Eli Lilly And Company	Polypeptide compositions with improved stability
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
AU2001220765A1 (en)	2000-01-24	2001-07-31	Medtronic Minimed, Inc.	Mixed buffer system for stabilizing polypeptide formulations
TR200401142T4 (tr)	2000-01-27	2004-07-21	Eli Lilly And Company	Glükagon-benzeri peptid bileşiklerinin çözündürülmesi için işlem.
EP1396499A3 (de)	2000-01-27	2004-12-29	Eli Lilly And Company	Verfahren zur Lösung von Glucagon-ähnlichen Peptid-1 (GLP-1) Verbindungen
US6844321B2 (en) *	2000-01-31	2005-01-18	Novo Nordisk A/S	Crystallization of a GLP-1 analogue
WO2001077141A1 (en)	2000-04-06	2001-10-18	Novo Nordisk A/S	Shock heat treatment of polypeptides
ATE424413T1 (de) *	2000-06-16	2009-03-15	Lilly Co Eli	Analoge des glucagon-ähnlichen peptids-1
CN1340549A (zh) *	2000-08-26	2002-03-20	徐州万邦生化制药有限公司	一种胰高血糖素制备工艺
JP4798833B2 (ja)	2000-10-24	2011-10-19	一般財団法人化学及血清療法研究所	加熱処理工程を含むヒト血清アルブミンの製造方法
EP1351984A2 (de) *	2000-12-13	2003-10-15	Eli Lilly And Company	Amidiertes glucagonähnliches peptid-1
US20020151467A1 (en) *	2000-12-21	2002-10-17	Leung Frank K.	Methods and compositions for oral insulin delivery
GB2371227A (en)	2001-01-10	2002-07-24	Grandis Biotech Gmbh	Crystallisation - resistant aqueous growth hormone formulations
ATE396202T1 (de) *	2001-02-16	2008-06-15	Conjuchem Biotechnologies Inc	Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
US6573237B2 (en) *	2001-03-16	2003-06-03	Eli Lilly And Company	Protein formulations
AU2002316811A1 (en) *	2001-06-28	2003-03-03	Novo Nordisk A/S	Stable formulation of modified glp-1
CN1335182A (zh)	2001-08-08	2002-02-13	华中科技大学	胰岛素口腔喷剂及其制备工艺
CA2458371A1 (en)	2001-08-23	2003-03-06	Eli Lilly And Company	Glucagon-like peptide-1 analogs
CA2452044A1 (en) *	2001-08-28	2003-03-13	Eli Lilly And Company	Pre-mixes of glp-1 and basal insulin
WO2003035099A1 (en)	2001-10-19	2003-05-01	Eli Lilly And Company	Biphasic mixtures of glp-1 and insulin
JP2005526084A (ja)	2002-03-15	2005-09-02	ナットイムネ・アクティーゼルスカブ	マンノース結合レクチンを含む医薬組成物
WO2003084563A1 (en) *	2002-04-04	2003-10-16	Novo Nordisk A/S	Glp-1 agonist and cardiovascular complications
DE60321473D1 (de)	2002-09-25	2008-07-17	Novo Nordisk As	Aufreinigungsverfahren, das eine mikrofiltration bei erhöhten temperaturen beinhaltet
US7273921B2 (en) *	2002-09-25	2007-09-25	Novo Nordisk A/S	Method for producing acylated peptides
WO2004089985A1 (en) *	2003-04-11	2004-10-21	Novo Nordisk A/S	Stable pharmaceutical compositions
EP1631308B1 (de)	2003-05-30	2013-07-31	Amylin Pharmaceuticals, LLC	Neue verfahren und zusammensetzungen für die verbesserte transmukosale abgabe von peptiden und proteinen
CA2527743A1 (en)	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
US20060287221A1 (en) *	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
EP1684793B1 (de)	2003-11-13	2011-09-21	Novo Nordisk A/S	Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)-insulin, und eine oberflächenaktive verbindung
WO2006025882A2 (en)	2004-08-25	2006-03-09	The Uab Research Foundation	Absorption enhancers for drug administration

2004
- 2004-06-03 AT AT04735870T patent/ATE541582T1/de active
- 2004-06-03 CN CN201210497503.5A patent/CN102940879B/zh not_active Expired - Lifetime
- 2004-06-03 EP EP10178212A patent/EP2292254A3/de not_active Withdrawn
- 2004-06-03 ES ES04735870T patent/ES2380437T3/es not_active Expired - Lifetime
- 2004-06-03 KR KR1020127027174A patent/KR101308912B1/ko not_active Expired - Lifetime
- 2004-06-03 BR BRPI0410972A patent/BRPI0410972C1/pt active IP Right Grant
- 2004-06-03 JP JP2006508132A patent/JP4936884B2/ja not_active Expired - Lifetime
2005
- 2005-11-30 US US11/290,634 patent/US7632806B2/en not_active Expired - Lifetime
2009
- 2009-11-05 US US12/612,888 patent/US8614181B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
KR101308912B1 (ko)	2013-09-23
BRPI0410972A (pt)	2006-07-04
US8614181B2 (en)	2013-12-24
EP2292254A2 (de)	2011-03-09
JP4936884B2 (ja)	2012-05-23
BRPI0410972B1 (pt)	2018-01-30
ES2380437T3 (es)	2012-05-11
US7632806B2 (en)	2009-12-15
CN102940879B (zh)	2017-06-06
BRPI0410972B8 (pt)	2018-12-04
KR20120130264A (ko)	2012-11-29
BRPI0410972C1 (pt)	2021-05-25
US20100056451A1 (en)	2010-03-04
CN102940879A (zh)	2013-02-27
EP2292254A3 (de)	2011-12-14
US20060178304A1 (en)	2006-08-10
JP2008500262A (ja)	2008-01-10

Publication	Publication Date	Title
ATE541582T1 (de)	2012-02-15	Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
MXPA05013048A (es)	2006-03-02	Composiciones peptodicas farmaceuticas estabilizadas.
ATE529126T1 (de)	2011-11-15	Stabilisierte pharmazeutische peptid zusammensetzungen
CY1115484T1 (el)	2017-01-04	Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
ATE450269T1 (de)	2009-12-15	Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
SE0100568D0 (sv)	2001-02-20	Compounds
CY1113299T1 (el)	2016-04-13	Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
WO2004032909A3 (en)	2004-07-01	Stabilized pharmaceutical composition containing basic excipients
FI20050932A7 (fi)	2005-11-18	Heterobifunktionaaliset polymeeriset biokonjugaatit
TNSN07238A1 (en)	2008-11-21	Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes. pharmaceutical formulations containing the same, and use thereof as medicaments
EA201000643A1 (ru)	2010-08-30	Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
DE60334773D1 (de)	2010-12-16	Formulierungen zur oralen verabreichung von wirkstoffen
MY138708A (en)	2009-07-31	Biaryloxymethylarenecarboxylic acids
WO2006058539A3 (en)	2006-10-26	Growth hormone secretagogue receptor 1a ligands
WO2005037798A3 (en)	2005-06-16	Amide or thiomide derivatives and their use in the treatment of pain
WO2005115470A3 (fr)	2007-03-22	COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
WO2006138608A3 (en)	2007-04-26	Pharmaceutical compositions and use thereof
NO20080552L (no)	2008-03-27	GLP-1 farmasoytiske sammensetninger
DE60215313D1 (de)	2006-11-23	Indolderivate und deren verwendung als gnrh antagonisten
WO2004087880A8 (en)	2005-01-13	Compounds and their use to treat diabetes and related disorders
DE60134735D1 (de)	2008-08-21	Neue neurokinin-antagonisten zum gebrauch als arzneimittel
EA200870223A1 (ru)	2009-02-27	Производные бензоизоиндола для лечения боли
WO2006020207A3 (en)	2007-01-18	Compounds for control of appetite
WO2006113718A3 (en)	2007-12-21	Compositions for the treatment of neoplasms
SE0101692D0 (sv)	2001-05-14	Compounds